Drug Search Results
More Filters [+]

Oxitriptan

Alternative Names: oxitriptan, 5-hydroxytryptophan, 5-htp
Latest Update: 2024-11-08
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: 5-HT Binder

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: France | India | Lithuania | Malta | Portugal | Slovenia | Spain | Taiwan | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Daniel F Fouladi
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Oxitriptan

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Hypoxia|Depressive Disorder, Major|Depressive Disorder, Treatment-Resistant

Phase 3: Spinal Cord Injuries

Phase 2: Obesity|Crohn Disease|Colitis, Ulcerative|Depressive Disorder, Major|Fragile X Syndrome|Asthma, Allergic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

IRB_00132830_R33

P2

Recruiting

Depressive Disorder, Major

2026-06-30

5-HTP only

P3

Recruiting

Spinal Cord Injuries

2025-06-30

Kloepfer_1902366300

P2

Recruiting

Asthma, Allergic

2024-12-01

IRB_00132830

P2

Completed

Depressive Disorder, Major

2023-08-01

Recent News Events